Hims & Hers Investors: Urgent Action Required Amidst Securities Fraud Claims
ByAinvest
Sunday, Jul 6, 2025 11:52 pm ET1min read
HIMS--
NVO--
Hims & Hers Health, Inc. (NYSE: HIMS) is facing a securities fraud class action. Investors who purchased Hims & Hers stock between April 29, 2025, and June 23, 2025, may move to be appointed lead plaintiff by August 25, 2025. The complaint alleges that Hims & Hers made false and misleading statements about its partnership with Novo Nordisk and failed to disclose material facts, resulting in a $22.24 per share, or 34.63%, decline in stock value. Investors can consult with a lawyer by visiting a specific website or contacting Edelson Lechtzin LLP at 844-696-7492 ext. 1.

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet